KVUE

Kenvue to Announce First Quarter 2024 Results on May 7, 2024

Retrieved on: 
Friday, April 5, 2024
Biotechnology, General Health, Other Health, Health, Medical Supplies, ID, Webcast, KVUE, Inc.

Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, will announce its financial results for the first quarter ending March 31, 2024, before market open on May 7, 2024.

Key Points: 
  • Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, will announce its financial results for the first quarter ending March 31, 2024, before market open on May 7, 2024.
  • The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results.
  • The conference call can be accessed by dialing 888-672-2415 from the U.S. or +1 646-307-1952 from international locations.
  • A live webcast of the conference call will be available at investors.kenvue.com .

Kenvue to Present at the Consumer Analyst Group of New York Conference on February 23, 2024

Retrieved on: 
Tuesday, February 13, 2024
Home Goods, Pharmaceutical, General Health, Health, Convenience Store, Cosmetics, Retail, Other Health, KVUE, Inc., Conference

Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced Thibaut Mongon, Chief Executive Officer, and Paul Ruh, Chief Financial Officer, will present at the Consumer Analyst Group of New York (CAGNY) Conference in Boca Raton, Florida, on Friday, February 23, 2024, at 10:00 a.m. Eastern Time.

Key Points: 
  • Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced Thibaut Mongon, Chief Executive Officer, and Paul Ruh, Chief Financial Officer, will present at the Consumer Analyst Group of New York (CAGNY) Conference in Boca Raton, Florida, on Friday, February 23, 2024, at 10:00 a.m. Eastern Time.
  • A live webcast of the session will be available at investors.kenvue.com and a replay will be available on the same website following the event.

Kenvue Reports Full Year and Fourth Quarter 2023 Results

Retrieved on: 
Thursday, February 8, 2024
Home Goods, Medical Supplies, Health, Medical Devices, Consumer, Other Consumer, Retail, Other Health, GAAP, Inc., Absorption, Interest, Organic, Cough, KVUE, ID, Culture, Insurance

Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced financial results for the fiscal full year and fourth quarter ended December 31, 2023.

Key Points: 
  • Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced financial results for the fiscal full year and fourth quarter ended December 31, 2023.
  • Fourth quarter Net sales decreased 2.7% vs a 0.9% increase in the prior year period.
  • Interest expense, net was $250 million for the year on a reported basis, and $96 million for fourth quarter 2023.
  • As previously announced, Kenvue will host a conference call with investors to discuss its fourth quarter results at 8:30 a.m. Eastern Time.

KENVUE ALERT: Bragar Eagel & Squire, P.C. is Investigating Kenvue Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, January 27, 2024
Risk, Telephone, Register, IPO, Prospectus, P.C, Phenylephrine, KVUE

NEW YORK, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Kenvue Inc. (NYSE: KVUE) on behalf of long-term stockholders following a class action complaint that was filed against Kenvue on October 9, 2023 with a Class Period pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with Kenvue’s initial public offering (the “IPO” or “Offering”).

Key Points: 
  • NEW YORK, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Kenvue Inc. (NYSE: KVUE) on behalf of long-term stockholders following a class action complaint that was filed against Kenvue on October 9, 2023 with a Class Period pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with Kenvue’s initial public offering (the “IPO” or “Offering”).
  • Our investigation concerns whether the board of directors of Kenvue have breached their fiduciary duties to the company.
  • If you are a long-term stockholder of Kenvue, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected] , by telephone at (212) 355-4648, or by filling out this contact form .
  • There is no cost or obligation to you.

TEGNA Stations KUSA and KVUE Win Prestigious 2024 Alfred I. duPont-Columbia University Awards

Retrieved on: 
Monday, January 29, 2024
TV and Radio, Entertainment, Digital, TGNA, KUSA, IA Financial Group, TEGNA, Justice, EVP, Justice minister, KVUE

TEGNA Inc. (NYSE: TGNA) today announced that KUSA (Denver, Colo.) and KVUE (Austin, Texas) received 2024 Alfred I. duPont-Columbia University Awards which honor excellence in broadcast, online and documentary journalism.

Key Points: 
  • TEGNA Inc. (NYSE: TGNA) today announced that KUSA (Denver, Colo.) and KVUE (Austin, Texas) received 2024 Alfred I. duPont-Columbia University Awards which honor excellence in broadcast, online and documentary journalism.
  • KUSA won for “BURNED,” a year-long project to document the devastating 2021 Marshall Fire in Boulder County.
  • KVUE was honored for “Accountability After Uvalde,” revealing the failures of law enforcement in the aftermath of the mass shooting at Robb Elementary in Uvalde, Texas.
  • "BURNED" is also the recipient of two National Edward R. Murrow Awards in the digital and documentary categories.

Kenvue Declares Quarterly Cash Dividend

Retrieved on: 
Thursday, January 25, 2024
Cosmetics, Medical Supplies, Retail, Health, Home Goods, Pharmaceutical, Inc., KVUE

Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced that its Board of Directors has declared a dividend payable in the first quarter of $0.20 per share on the Company’s common stock.

Key Points: 
  • Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced that its Board of Directors has declared a dividend payable in the first quarter of $0.20 per share on the Company’s common stock.
  • The first quarter dividend is payable on February 28, 2024 to shareholders of record as of the close of business on February 14, 2024.

Kenvue to Announce Fourth Quarter and Full Year 2023 Results on February 8, 2024

Retrieved on: 
Friday, January 5, 2024
Retail, Home Goods, General Health, Health, Webcast, ID, KVUE, Inc.

Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, will announce its financial results for the fourth quarter and full year ending December 31, 2023, before market open on February 8, 2024.

Key Points: 
  • Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, will announce its financial results for the fourth quarter and full year ending December 31, 2023, before market open on February 8, 2024.
  • The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results.
  • The conference call can be accessed by dialing 888-660-5501 from the U.S. or 646-960-0416 from international locations.
  • A live webcast of the conference call will be available at https://investors.kenvue.com .

KVUE DEADLINE ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Kenvue Inc. Investors to Secure Counsel Before Important December 8 Deadline in Securities Class Action First Filed by the Firm - KVUE

Retrieved on: 
Saturday, December 2, 2023
Titan, Phenylephrine, Court, Register, KVUE, Plaintiff, Prospectus, Advertising, Tobacco

WHAT TO DO NEXT: To join the Kenvue class action, go to https://rosenlegal.com/submit-form/?case_id=19241 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Kenvue class action, go to https://rosenlegal.com/submit-form/?case_id=19241 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

KVUE DEADLINE ALERT: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Kenvue Inc. Investors to Secure Counsel Before Important December 8 Deadline in Securities Class Action First Filed by the Firm - KVUE

Retrieved on: 
Thursday, November 30, 2023
Titan, Phenylephrine, Court, Register, KVUE, Plaintiff, Prospectus, Advertising, Tobacco

WHAT TO DO NEXT: To join the Kenvue class action, go to https://rosenlegal.com/submit-form/?case_id=19241 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Kenvue class action, go to https://rosenlegal.com/submit-form/?case_id=19241 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

KVUE FINAL DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Kenvue, Inc. (KVUE) Investors with Substantial Losses to Contact its Attorneys Before Dec. 8th Deadline in Securities Class Action

Retrieved on: 
Thursday, December 7, 2023
FDA, IPO, KVUE, Person, Hagens Berman, Risk, Phenylephrine, Pharmaceutical industry

On or around Sept. 12, 2023, the FDA published a briefing document announcing that it was convening an advisory committee to discuss efficacy data available for orally administered phenylephrine as a nasal decongestant.

Key Points: 
  • On or around Sept. 12, 2023, the FDA published a briefing document announcing that it was convening an advisory committee to discuss efficacy data available for orally administered phenylephrine as a nasal decongestant.
  • “We’re focused on investors’ losses and investigating whether Kenvue adequately disclosed commercial risks related to its products containing PE,” said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.
  • For more information, call Reed Kathrein at 844-916-0895 or email [email protected] .